Gene therapy trial for genetic frontotemporal dementia
Part of Brain & nervous system, Hormones & metabolism, Mental health clinical trials.
This trial tests a new gene therapy called AVB-101 for people with a specific genetic cause of frontotemporal dementia (FTD). The therapy is given as a one-time injection into the brain to potentially slow or stop the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 30 and 75 years old
- You have a known genetic mutation in the GRN gene
- Your dementia symptoms are mild to moderate (not severe)
- You have symptoms consistent with frontotemporal dementia (bvFTD or PPA)
- You have a family member or friend who can support you throughout the study
- You have not had any prior gene or cell therapy treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study recruits adults who come from families with certain known gene changes linked to frontotemporal dementia. It aims to learn more about these inherited forms of dementia using brain scans and research blood testing, which will not provide personal results.
This study looks at complex brain and body changes in people with ALS and frontotemporal dementia (FTD), or related disorders. If you have one of these diagnoses—or a known gene mutation that can cause ALS/FTD—you may be able to help researchers learn how the conditions progress.
This study tests an investigational treatment for people with a specific type of frontotemporal dementia called semantic variant. It aims to see if the treatment is safe and can slow down the disease.
This study follows young people ages 9 to 16 who have a close biological family member with genetic frontotemporal dementia (FTD). It aims to better understand this inherited condition and track participants over time. You may complete surveys and thinking/behavior assessments, and you may have brain MRI scans if you choose.
This trial tests a new gene therapy delivered directly into the brain to help control Parkinson's symptoms. It is for people with advanced Parkinson's disease who still have significant movement problems despite their current medications.
This trial tests a new gene therapy for Parkinson's disease. The therapy is delivered directly into the brain during a surgical procedure, with the goal of improving motor symptoms and reducing 'off' time.
Hear when a new Frontotemporal Dementia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.